Literature DB >> 6627254

Lipids associated with rat small-intestinal mucus glycoprotein.

H Witas, J Sarosiek, M Aono, V L Murty, A Slomiany, B L Slomiany.   

Abstract

The lipid content and composition of rat small-intestinal mucus, and the purified mucus glycoprotein before and after Pronase digestion were investigated. The mucus, obtained by the instillation of intestine with 2M NaCl, was fractionated on Bio-Gel A-50 in the presence of 6M urea and the mucus glycoprotein free of noncovalently bound protein was isolated. A portion of the purified glycoprotein was subjected to Pronase digestion to yield glycopeptides. The native mucus, and the purified glycoprotein and glycopeptides were extracted with chloroform-methanol, and the lipids contained in the extracts were analyzed. The lipids accounted for 17.6 of the dry weight of mucus, 26.4 of the mucus glycoprotein, and 25.3% of the glycopeptides. In comparison to mucus, the lipids associated with mucus glycoprotein contained 1.9 times more phospholipids and 2.1 times more glycolipids, showed a 26% increase in neutral lipids, and were virtually free of glycosphingolipids. Treatment of the purified glycoprotein with Pronase led to a moderate (22.3%) loss in neutral lipids, 4.3-fold decrease in phospholipids, and 52.3% increase in glyceroglucolipids. The results indicate that while the interaction of mucus glycoprotein with phospholipids involves its Pronase-susceptible region, the interaction with glyceroglucolipids occurs in the glycosylated region of the glycoprotein that is resistant to proteolysis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6627254     DOI: 10.1016/0008-6215(83)88007-0

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  11 in total

Review 1.  Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers.

Authors:  Laura M Ensign; Richard Cone; Justin Hanes
Journal:  Adv Drug Deliv Rev       Date:  2011-12-24       Impact factor: 15.470

2.  Hydrophilic-lipophilic balance as predictor of mucus coating with barium sulfate.

Authors:  E Salomonowitz; M P Frick; R L Morin; S Meryn
Journal:  Gastrointest Radiol       Date:  1986

3.  Diffusivity of bile salt/phospholipid aggregates in mucin.

Authors:  C Y Li; C L Zimmerman; T S Wiedmann
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

4.  Biocoating-A Critical Step Governing the Oral Delivery of Polymeric Nanoparticles.

Authors:  Aharon Azagury; Cameron Baptista; Kosta Milovanovic; Hyeseon Shin; Peter Morello; James Perez-Rogers; Victoria Goldenshtein; Travis Nguyen; Arianna Markel; Soham Rege; Stephanie Hojsak; Alexander Perl; Carder Jones; Megan Fife; Stacia Furtado; Edith Mathiowitz
Journal:  Small       Date:  2022-05-23       Impact factor: 15.153

5.  Biosynthesis of proteins by human gastric mucosa in vitro.

Authors:  M Spohn; I McColl
Journal:  Biochem J       Date:  1987-03-01       Impact factor: 3.857

6.  Phosphatidylserine found in intestinal mucus serves as a sole source of carbon and nitrogen for salmonellae and Escherichia coli.

Authors:  H C Krivan; D P Franklin; W Wang; D C Laux; P S Cohen
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

7.  Binding of Yersinia enterocolitica to purified, native small intestinal mucins from rabbits and humans involves interactions with the mucin carbohydrate moiety.

Authors:  M Mantle; S D Husar
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

8.  Degradation of pig gastric and colonic mucins by bacteria isolated from the pig colon.

Authors:  R A Stanley; S P Ram; R K Wilkinson; A M Roberton
Journal:  Appl Environ Microbiol       Date:  1986-05       Impact factor: 4.792

Review 9.  The role of airway mucus in pulmonary toxicology.

Authors:  J M Samet; P W Cheng
Journal:  Environ Health Perspect       Date:  1994-06       Impact factor: 9.031

Review 10.  Innate antiviral defenses in body fluids and tissues.

Authors:  S Baron; I Singh; A Chopra; D Coppenhaver; J Pan
Journal:  Antiviral Res       Date:  2000-11       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.